Highlights OpGen, Inc.

Equities

OPGN

US68373L5057

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
2.58 ^USD	+1.98%		+7.05%	-38.57%

06-03	OpGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
05-30	OpGen, Inc. Announces Appointments to the Committees of the Board	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OpGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06-03	CI
OpGen Gets Notice of Noncompliance From Nasdaq	04-24	MT
Earnings Flash (OPGN) OPGEN Posts Q3 Revenue $699,022	11-14	MT
OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
OpGen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (OPGN) OPGEN Reports Q2 Revenue $736,136, vs. Street Est of $900,000	23-08-10	MT
Earnings Flash (OPGN) OPGEN Posts Q1 Revenue $0.91M	23-05-15	MT
OpGen, Inc. Provides Revenue Guidance for the Year 2023	23-05-15	CI
OpGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
OpGen, Fisher Healthcare Sign Non-Exclusive Distribution Agreement for Unyvero A50 Platform	23-04-18	MT
Opgen, Inc. Submits De Novo Request to the U.S. FDA for Unyvero Urinary Tract Infection Panel	23-04-18	CI
OpGen, Inc. Enters into Non-Exclusive Distribution Agreement with Fisher Healthcare	23-04-18	CI
OpGen Files De Novo Market Authorization Request With US FDA for Urinary Tract Infection Panel, Shares Rise Pre-Bell	23-04-18	MT
OpGen Unit Expands Research, Development Collaboration With FIND	23-04-05	MT
Earnings Flash (OPGN) OPGEN Reports Q4 Revenue $721,630	23-03-29	MT
OpGen, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-29	CI
OpGen, Inc. Announced Unaudited Preliminary Revenue Results for Full Year 2022	23-01-18	CI
OpGen Implements 1-for-20 Reverse Stock Split	23-01-05	MT
OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel	22-12-13	CI
OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OpGen, Inc.

Equities

OPGN

US68373L5057

Highlights

Filters